Results of conventional karyotyping, subtelomeric FISH studies and targeted testing of CREBBP were normal. We then performed high resolution chromosomal microarray testing which did not reveal any apparent pathologic variant followed by WES in P1 and trio-WES in P2 and P3 and their healthy parents. The study was approved by the ethical committee of the canton of Zurich. Filtering for rare, non-synonymous exonic, and splice site variants in 821 known and 424 candidate ID genes (based on the SysID database, [Kochinke et al., 2016] ), considering both dominant and recessive modes of inheritance, revealed pathogenic de novo loss of function mutations in ARID1B in P2 and P3. In P2, we identified a heterozygous deletion of 4 bp (NM_020732.3:c.5570_5573del) in the last coding exon of ARID1B, which causes a frameshift resulting in a premature truncation after 16 amino acids and thereafter a c.4110G>A), which was predicted to be synonymous, but located in the conserved consensus splice donor site. This mutation had been reported previously in a patient with nonspecific ID and results in skipping of exon 17 in RNA from patient lymphocytes (Hoyer et al., 2012) . Therefore, it was predicted to cause a frameshift resulting in a premature translational termination (p.His1339Ilefs*77); and thus, possibly in nonsense-mediated mRNA-decay. In P1, no obvious pathogenic or likely pathogenic loss of function mutation in a known ID gene could be detected, although the whole coding region of ARID1B was covered at least 20-fold and MLPA analysis showed normal dosage for all exons. Of note, additional mutation screening of all variants in related ID genes (ARID1B, SMARCA4, SMARCB1, SMARCE1, SMARCA2, TBC1D24, SOX11, PHF6, TBC1D24, ADNP, and KMT2A) revealed no obvious pathogenic variant, either. However, interpretation of missense variants in other genes and analysis of novel candidate genes were hampered by the fact that the father was not available and a trio approach therefore not feasible.
Our findings establish mutations in ARID1B as the underlying genetic defect in the HHID syndrome in two of three patients.
The underlying genetic defect in P1 remains currently elusive, however, an undetected non-coding mutation of ARID1B cannot be excluded.
Haploinsufficiency of ARID1B was recently implicated in both, nonsyndromic ID and Coffin-Siris Syndrome (CSS, OMIM #135900) (Hoyer et al., 2012; Santen et al., 2012; Tsurusaki et al., 2012) . There is accumulating evidence that ARID1B is one of the most commonly mutated genes in ID and is associated with a broad phenotypic range (Deciphering Developmental Disorders, 2015; Hoyer et al., 2012; Santen & Clayton-Smith, 2014) . The core phenotype of ARID1B mutated patients, present in almost all patients with a prior CSS diagnosis, comprises ID (100%), speech delay (100%), "coarse facies" (95%), and hypertrichosis (95%). Common further anomalies were small 5th finger or toe nails (81%), short fifth finger (73%), feeding difficulties (65%), agenesis of the corpus callosum (35%), seizures (23%), myopia (20%), and growth delay (19% height <−2.5 SDS, 71%
height <0 SDS) (Santen & Clayton-Smith, 2014) . Retrospectively, the HHID patients' phenotypes fit well into the published ARID1B-associated clinical spectrum including the key features of ID, hypertrichosis, abnormal corpus callosum, and coarse face. However, our patients show only mildly diminished nail size and demonstrate that the key feature of hypertrichosis vanishes to levels of normal variation during adolescence. Moreover, the most distinctive feature shared by all patients with suspected HHID (Dalal & Mehrotra, 2009; Pöyhönen et al., 2004 ) is the ectodermal sign of hyperkeratotic plaques which has not yet been reported in any patient with CSS or ARID1B-associated nonspecific ID. This might therefore constitute either an underreported or an infrequent but distinct novel feature of ARID1B-associated phenotypes. However, reevaluation of patients with ARID1B mutations is needed to assess the true incidence of FIGURE 1 Phenotypes of patients with suspected HHID syndrome at clinical reinvestigation after about 10 years. Facial gestalt, hand and foot, and a location with hyperkeratotic plaques is shown for P1 at the age of 25 years (A-E), for P2 at the age of 26 years (F-J), and for P3 at the age of 19 years (K-N). Of note, the picture with hyperkeratotic plaques for P3 (O) was taken at the age of 16 years hyperkeratotic plaques, which may become only obvious with increasing age.
